BAO Laboratory What Causes Uneven Skin Tone?
Overview
In 2026 dermatology formulation practice, uneven skin tone is no longer understood as mere melanin imbalance. It is conceptualized as a multi-layer optical modulation system: a melanin gets mixed with vascular visibility and barrier translucency - they ‘play’ with each other as filers do.
This “layering tactic” explains why we see a common pattern in OEM clinical data at Asian and EU labs: two subjects who display ‘similar’ levels of skin pigmentation may have their active and visible “tone evenness” vary dramatically, depending on their background of inflammation, and barrier integrity, even if their melanin load is similar.
A key correction we are learning as formulation engineers: the problem isn’t always pigment load - uneven tone appearance often stems from how the skin scatters and reveals what’s stocked up, rather than just what’s stocked up.
The Three Structural Layers Behind Uneven Skin Tone
1. The ‘Pigment’ Layer: Melanin Distribution Frailty
What gets us unevenness related to pigment down to is driven by how melanocytes behave when it comes to their activity and transfer.
In clinical terms, this means:
melanin overreaction to UV or inflammation
uneven transfer into keratinocyte homes
slow epidermal turnover
The TV celebrities of this world class and soft-focus, Tranexamic Acid and azelaic acid primarily here, by calming down inflammatory signalling and pigment transfer to the keratinocyte home. And yet, the lab data have consistently shown us the missing component - suppressing pigment alone does not produce a ‘visibly even tone’ unless vascularity and epidermal components are curtailed as well.
The Vascular Layer: Seeing Red
A classic offender for unevenness that tends to be missed in early phase skin condition design is the ‘persistence of vasculature’.Post-inflammatory erythema (PIE) is distinct from pigmentation:
· vascular-mediated - due to capillary dilation.
· due to incomplete resolution from inflammation
· gradual return to “normal” circulation.
In 2026 imaging datasets using cross-polarized dermoscopy, this vascular redness alone contributes to 30-45% of the perceived unevenness of a fair-to-medium skin tone, even with clinically mild levels of pigment.
This is why that you see “my dark spots improved, but my skin doesn’t look even.”
Barrier Optical Layer: Scattering + Inward “Translucency” Shift
The most underrated aspect of this is the compromised state of the barrier.
When the microbiome of the stratum corneum is disrupted, you are:
· losing Transepidermal Water Loss
· light scattering looks different
· keratinocytes are no longer cross-hatch aligned.
The skin will now not scatter light evenly, which leads to patchy, even without a super heavy transition in pigment.
Using OEM simulation models, we’ve shown that simply restoring this barrier effect can improve the perceived even tone of the skin by 18-35%
without impacting the pigment.
Why “brightening” serums plateau.
In global datasets, a pattern is emerging.
High melanin reduction on its own does not equal a unified look.
Where is the bottleneck? It’s not just how much melanin signal is suppressed, but looking at the skin as a tree, as many layers playing a role in expressing tone. What’s typically happening is ”my skin lightened/brightened, but also a patchier look”.
Pigment fades too fast for vasculature to reconcile
Barrier still partly inflamed
Congruence breaks across layers, increasing perception of contrast
Where have you guys seen this? This is where you may tell us that “my skin improved in tone, but now looks patchier”.
Key Actives & What Their Real Use Cases Are Boundaries
Tranexamic Acid
· “Hey, do I just take this and then my skin is whitening?” No. That’s not how it works.
Basically, it works by lowering the inflammatory signal for the underlying pigment, not just attempting to bleach the actual melanin out.
Performance characteristics:
best on post-inflammatory pigmentation (PIH)
moderate effect on melasma
weak on dermal-level pigmentation
Clinical timing window:
visible tone stabilization in 3–6 weeks
stronger outcomes when inflammation is already resolved
A recurring formulation insight: TXA performs significantly better in barrier supported systems than in isolated high-dose serums.
Niacinamide: Transfer Control + Barrier Rebalancing
Niacinamide improves tone evenness through:
reduced melanosome transfer
increased ceramide synthesis
TEWL reduction
Dose-dependent behavior:
2–5%: optimal balance of tone + barrier
higher concentrations: increased irritation risk in compromised skin
Clinical datasets show niacinamide rarely clears pigmentation alone, but it significantly improves tone homogeneity when combined with repair systems for the barrier.
Retinoids: Turnover Synchronization Layer
Retinoids improve uneven tone through accelerated epidermal renewal.
Observed 2026 behavior:
initial irritation phase in 20-35% of users
Harest visible tone alignment in 6-10 weeks of use
effect strongest on micro texture irregularity rather than pigment depth
A practical constraint: excessive use of retinoids during periods of active inflammation worsens the perceived unevenness of skin tone due to desynchronization of barrier status and appearance.
The Most Misunderstood Mechanism: “Optical Mismatch”
One consistent observation from imaging based dermatology systems is this:
Skin looks uneven even when pigment is technically improving.
This occurs when:
pigment is receding but vascular recovery is slower
skin hydration is less than optimal in certain zones of a face
micro inflammation is still occurring below clinical detection.
In lab modelling we describe this as a desynchronization between pigment, vascular, and barrier recovery curves.Until these are evenly matched, tone remains visually uneven.
Why “Natural Brightening” Isn’t Always Natural
Natural brightening regimes often use certain antioxidants and very gentle botanical inhibitors and in internal testing:
antioxidant-only systems can improve oxidative stress metrics
but prove fairly limited re vascular or barrier, ie bottom-up driven unevenness
This is why the tone results plateau quite early in phase unless you’re also including:
anti-inflammation agents (TXA, azelaic acid)
barrier lipid levels
controlled turnover agents
Skin-Type Induced Patterns of Uneven Tone
Acne Duality
Main cause:
PIH + residual inflammation
Best system:
azelaic acid + TXA
controlled ramp-in of retinoid
strict barrier lips
Sensitive / Redness
Cause semaphoring:
vascular persistence + barrier fragility
Best system:
TXA solo
ceramide Ergonomist
low mild frequency of exfoliation
Vigorous brightening in this group typically just lengthens the chronological duration of uneven tone.
Mature Skin (eg 40s/50s)
Primary driver:
slower turnover + dermal thinning + vascular visibility increasing
Best system:
low dose retinoids
peptide elasticated dynamic
lipid barrier reconstructors
TXA as toning stabiliser
A complexity seen in clinical imaging: you often find altering texture towards “improvement” can worsen apparent unevenness during the interim vis-a-vis initial opacity, because the translucency imparts a perception of more inconsistency, until longer term unity creeps in.
Barrier Repair as the Silent Equalizer
In our OEM simulation systems, restoring barrier gets some of the best overall tone uniformity improvements:
mechanistically:
less TEWL equals better optical consistency
reduction in inflammation signalling
higher synchrony in pigment clearing
Any formulations that include:
ceramides
cholesterol + fatty acid (ie 3:1:1 lipid structure models)
panthenol or beta-glucan
routinely outperform leading “brightening only” actives algorithms by quite a lot in evenness scoring.
In our lab datasets barrier-first systems drive 20-40% generally “improved visible uniformity” metrics even prior to acting as an efficacy booster for pigment active concentration.
Decision Logic We Used in Designing 2026 Formulations
Step 1 - establish what mostly is “engine of unevenness“
brown/grey dominant colour input - ie driven by pigment
red/pink dominant input - ie driven by vascular, ie bottom-up
mixed colour input - cross section of barrier + inflammation
Step 2 - choose main correction sequence:
pigment vehicle - TXA + azelaic as two actives side by side
vascular, ie low fly of vascular drivers - barrier + anti Inflammant
mixed - sequencial, not stacked
Step 3 - choose tolerance bandwidth
high bandwidth - retinoid can be allowed, a la carte wise
medium bandwidth - alternating
low bandwidth - a stabilizing sort of barrier netting first
2026 Directional Trends: Sounding United Tone Phase Systems
Moving away from verb, ie”brightening versus anti aging versus acne”
Current development typings:
multi cavalcade system pathwayscorrection, ie pigman, vascular and barrier
encapsulated actives that volume down peaks of irritation
spiked AI skinmaps of sensitivity
barrier first formulations
A change in the OEM language: “success” is defined by the rigidity of tone uniformity imparted, rather than speedy lightening, a tone overall metric of success, is looked for.
What Actually Drives You Looking Even/Different?
In our clinical datasets, three things tend to dominate outcome:
degree of inflammation resolution achieved
speed of barrier recovery
speed and uniformity of UV perturbation control
Actives can influence how fast you drive a change in skin, but not whether pigment, vascular response and barrier optics converge on “actually” looking even/different. That convergence is where a lot of this work now lies, in terms of resolving or elongating the uneven cases.